New Study Precisely Characterizes Tumor Heterogeneity in AML Patients Using Mission Bio's Tapestri Platform
Validates multi-omics techniques for measuring therapeutic responses to AML, holding promise for future blood cancer treatments
News provided by
Share this article
Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, today announced a new study published in
Nature Communications using its Tapestri Platform to perform high-throughput single-cell proteogenomic profiling to precisely characterize tumor heterogeneity in three acute myeloid leukemia (AML) patients across multiple treatment time points.
In conventional AML studies, DNA sequencing and flow cytometry have been used to assess disease genotype and immunophenotype, respectively. However, because a cell's underlying DNA mutation or co-occurring mutations may not robustly predict its immunophenotype, the measurement of these parameters in separate assays does not fully characterize the clones, and thus, the heterogeneity of disease. Authors of the new study from University of California, San Francisco, including Mission Bio co-founder Professor Adam Abate, showed that the genotype-immunophenotype associations of clones in two AML patients were discordant — underscoring the multifaceted nature of the disease. This breakthrough was only possible thanks to the multi-omics capability of the Tapestri Platform.